Noninvasive imaging of human telomerase reverse transcriptase (hTERT) messenger RNA with 99mTc-radiolabeled antisense probes in malignant tumors

Journal of Nuclear Medicine

Volumn 48, Issue 12, 2007, Pages 2028-2036

  Liu, Meng ^a   Rong, Fu Wang ^a   Chun, Li Zhang ^a   Yan, Ping ^a   Ming, Ming Yu ^a   Li, Juan Di ^a   Hong, Jie Liu ^a   Feng, Qin Guo ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

99mTc; Antisense; Biodistribution; hTERT; Human telomerase reverse transcriptase; Molecular imaging

Indexed keywords

TECHNETIUM 99M; TELOMERASE REVERSE TRANSCRIPTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG DISTRIBUTION; IN VIVO STUDY; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCINTILLATION CAMERA;

ANIMALS; CELL LINE, TUMOR; DRUG STABILITY; FEMALE; HUMANS; ISOTOPE LABELING; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TECHNETIUM TC 99M MERTIATIDE; TELOMERASE; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 36849029717     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.042622     Document Type: Article

References (37)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
2. Beattie TL, Zhou W, Robinson MO, Harrington L. Reconstitution of human telomerase activity in vitro. Curr Biol. 1998;8:177-180.
3. Chang JT, Chen YL, Yang HT, Chen CY, Cheng AJ. Differential regulation of telomerase activity by six telomerase subunits. Eur J Biochem. 2002;269:3442-3450.
4. Wirth T, Kühnel F, Kubicka S. Telomerase-dependent gene therapy. Curr Mol Med. 2005;5:243-251.
5. Hiyama E, Hiyama K. Telomerase as tumor marker. Cancer Lett. 2003;194:221-233.
6. Lee KH, Rudolph KL, Ju YJ, et al. Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Natl Acad Sci USA. 2001;98:3381-3386.
7. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17:545-580.
8. Blasberg R. PET imaging of gene expression. Eur J Cancer. 2002;38:2137-2146.
9. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Keith WN, Vassaux G. Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res. 2004;64:4906-4911.
10. Padmanabhan P, Otero J, Ray P, et al. Visualization of telomerase reverse transcriptase (hTERT) promoter activity using a trimodality fusion reporter construct. J Nucl Med. 2006;47:270-277.
11. Saji H. Development of radiopharmaceuticals for molecular imaging. Int Congr Ser. 2004;1264:139-147.
12. 99mTc-labeled antisense DNA. J Nucl Med. 2001;42:1660-1669.
13. 3 for technetium-99m labeling of DNA. Nucl Med Biol. 1997;24:425-432.
14. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene. 2001;269:1-12.
15. Orlando C, Gelmini S, Selli C, Pazzagli M. Telomerase in urological malignancy. J Urol. 2001;166:666-673.
16. Zhang Y, He DM. Effect of antisense hTERT mRNA oligodeoxynucleotide on telomerase activity of leukemic cells. Cell Biol Int. 2002;26:427-431.
17. Dewanjee MK, Ghafouripour AK, Kapadvanjwala M, et al. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. J Nucl Med. 1994;35:1054-1063.
18. Tian X, Aruva MR, Rao PS, et al. Imaging oncogene expression. Ann NY Acad Sci. 2003;1002:165-188.
19. Nakamura K, Kubo A, Hnatowich DJ. Antisense targeting of P-glycoprotein expression in tissue culture. J Nucl Med. 2005;46:509-513.
20. 99mTc-peptide-peptide nucleic acid-peptide chimeras. J Nucl Med. 2004;45:2070-2082.
21. Bai J, Yokoyama K, Kinuya S, et al. In vitro detection of mdr1 mRNA in murine leukemia cells with 111In-labeled oligonucleotide. Eur J Nucl Med Mol Imaging. 2004;31:1523-1529.
22. Gallazzi F, Wang Y, Jia F, et al. Synthesis of radiometal-labeled and fluorescent cell-permeating peptide-PNA conjugates for targeting the bcl-2 proto-oncogene. Bioconjug Chem. 2003;14:1083-1095.
23. 68Ga-labelled phosphodiester, phosphorothioate, and 2′-O-methyl phosphodiester oligonucleotides in normal rats. Eur J Pharm Sci. 2005;26:26-38.
24. Sun X, Fang H, Li X, Rossin R, Welch MJ, Taylor JS. MicroPET imaging of MCF-7 tumors in mice via unr mRNA-targeted peptide nucleic acids. Bioconjug Chem. 2005;16:294-305.
25. Wang RF, Shen J, Zhang CL, Liu M, Guo FQ. Study on biodistribution and imaging of radioiodinated antisense oligonucleotides in nude mice bearing human lymphoma [abstract]. J Nucl Med. 2006;47(5 suppl 2):428P.
26. Touboul M, Gauchez AS, D'Hardemare Adu M, et al. Early detection of chemoresistance in vivo through the use of a radiolabeled antisense oligonucleotide. Anticancer Res. 2002;22:3349-3356.
27. Vickers TA, Wyatt JR, Freier SM. Effects of RNA secondary structure on cellular antisense activity. Nucleic Acids Res. 2000;28:1340-1347.
28. Scherr M, Rossi JJ, Sczakiel G, Patzel V. RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res. 2000;28:2455-2461.
29. Gauchez AS, Du Moulinet D'Hardemare A, Lunardi J, Vuillez JP, Fagret D. Potential use of radiolabeled antisense oligonucleotides in oncology. Anticancer Res. 1999;19:4989-4997.
30. Kraemer K, Fuessel S, Schmidt U, et al. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res. 2003;9:3794-3800.
31. Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer: the time of truth. Lancet Oncol. 2002;3:672-683.
32. Britz-Cunningham SH, Adelstein SJ. Molecular targeting with radionuclides: state of the science. J Nucl Med. 2003;44:1945-1961.
33. Haberkorn U, Mier W, Eisenhut M. Scintigraphic imaging of gene expression and gene transfer. Curr Med Chem. 2005;12:779-794.
34. Dodds E, Dunckley MG, Naujoks K, Michaelis U, Dickson G. Lipofection of cultured mouse muscle cells: a direct comparison of lipofectamine and DOSPER. Gene Ther. 1998;5:542-551.
35. Schofield JP, Caskey CT. Non-viral approaches to gene therapy. Br Med Bull. 1995;51:56-71.
36. Hnatowich DJ, Nakamura K. Antisense targeting in cell culture with radiolabeled DNAs: a brief review of recent progress. Ann Nucl Med. 2004;18:363-368.
37. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer. 2005;5:468-479.